Role of Plasma Exchange in ABO-incompatible Kidney Transplantation

Soohun Yoo, M.D.1, Eun Young Lee, M.D.1, Kyu Ha Huh, M.D.2, Myoung Soo Kim, M.D.2, Yu Seun Kim, M.D.2, and Hyun Ok Kim, M.D.1

Departments of Laboratory Medicine1 and Surgery2, Yonsei University Health System, Seoul, Korea

Background: In the past, ABO incompatibility was an absolute contraindication for solid organ transplantation. However, multiple recent trials have suggested strategies for overcoming the reactions between graft antigens and recipient antibodies that cause graft rejection. In this study, we determined the usefulness of plasma exchange (PE) for removing anti-A/B antibodies that cause hyperacute/acute humoral graft rejection in patients undergoing ABO-incompatible kidney transplantation.

Methods: In our study, 12 patients underwent ABO-incompatible kidney transplantation. All recipients received pre-transplantation conditioning by PE or intravenous immunoglobulin (IVIG) administration. After pre-transplantation conditioning, anti-A/B antibody titers were evaluated, and transplantation was performed when the titer was below 1:8. To assess the transplantation outcome, anti-A/B antibody titers, creatinine level, estimated glomerular filtration rate (eGFR), and proteinuria levels were measured.

Results: Anti-A/B antibody titers were below 1:8 in all patients at the time of transplantation. eGFR measured on post-transplant day 14 showed that 10 patients had immediate recovery of graft function, while 2 patients had slow recovery of graft function. Short-term outcomes of ABO-incompatible kidney transplantation (measured as creatinine levels) after reducing anti-A/B antibody titers were similar to those of ABO-compatible kidney transplantation. After transplantation, the anti-A/B antibody titers were below 1:8 in 7 patients, but the remaining 5 patients required post-transplantation PE and IVIG treatment to prevent antigen-antibody reactions.

Conclusions: With the increasing demand for kidney donations, interest in overcoming the ABO incompatibility barrier has increased. PE may be an important breakthrough in increasing the availability of kidneys for transplantation.

Key Words: Plasma exchange, ABO blood-group system, Blood group incompatibility, Kidney transplantation

INTRODUCTION

For patients with chronic kidney disease, kidney transplantation is preferred over dialysis, because of the significantly superior survival rates of kidney transplantation. However, many patients are unable to receive transplants due to ABO mismatch. In Korea, patients awaiting kidney transplantation numbered 8,488 in 2009, and only about 15% of these patients received kidney transplantation [1]. If ABO-incompatible kidney transplantations were possible, many more kidney transplantations could be performed.

To overcome the ABO incompatibility barrier, trials have attempted to prevent the ABO antigen-antibody reactions to the graft. To prevent attack of anti-A/B antibodies on graft antigens,
anti-A/B antibody titers of the recipient must be reduced. Many reports on ABO-incompatible kidney transplantation have described the removal of anti-A/B antibodies using therapeutic plasma exchanges (PEs). For removing anti-A/B antibodies, removal of a recipient’s plasma through PE is reasonable. However, despite the historic and wide usage of therapeutic apheresis, controlled clinical trials on PE for ABO-incompatible kidney transplantation have not been conducted [2]. In previous years, desensitization protocols involving splenectomy to induce a reduction in lymphoid mass and enhance efficacy of immunosuppressive medications were developed [3]. However, adverse effects and suboptimal efficacy were noted after splenectomy. Currently, studies are being conducted on the use of PE and intravenous immunoglobulin (IVIG), along with immunosuppressants, but without splenectomy [4]. This study reports 12 cases of ABO-incompatible kidney transplantation that received PE followed by IVIG and immunosuppressant administration.

METHODS

1. Patients
Between June 2010 and May 2011, 12 patients received kidney transplantations from ABO-incompatible living donors at the Yonsei University Health System (YUHS), which is affiliated with Severance Hospital, Seoul, Korea. These patients had end stage renal disease and were unable to find ABO-compatible donors; however, each of them had a family member who intended to donate his or her kidney. All patients received pre-transplantation conditioning prior to the operation. Results of the HLA crossmatch test that included testing of the antihuman-globulin phase were negative for all patients.

2. Protocol for pre-transplantation conditioning
We used the conditioning protocol illustrated in Fig. 1, as previously reported [5]. The YUHS protocol consists of PE followed by IVIG (100 mg/kg) and immunosuppressants (tacrolimus 0.1 mg/day, mycophenolate 1,500 mg/day, prednisone 20 mg/day, rituximab 375 mg/m²) administration. The medical staff explained the pre-transplantation conditioning protocol to all patients, and all patients provided informed consent for the protocol. PE was conducted using the COBE spectra system (Gambror BCT, Lakewood, CO, USA) for the patients who had anti-A/B antibody titers greater than 1:8. One plasma volume was removed from each patient, and 100% replacement was provided using a 5% albumin solution and fresh frozen plasma (FFP) of AB blood group. PE and IVIG treatments were conducted every other day before transplantation until both IgM and IgG titers were under 1:8. PE was performed with 5% normal serum albumin for the initial sessions, and the last 2 sessions of PE were carried out with AB blood group FFP. Immunosuppressive drugs were used before transplantation to prevent graft rejection. Administration of tacrolimus, mycophenolate, and prednisone was initiated 7 days prior to transplantation, and administration of rituximab was performed 2 days before transplantation. Splenectomy was not included in the conditioning protocol.

3. Measurement of anti-A/B antibody titers
Anti-A/B antibody titers were determined by testing two-fold serial dilutions of the patients’ serum with commercially available A/B indicator red cells [6]. The highest serum dilution ratio that showed 1+ reactivity indicated the anti-A/B antibody titers. IgG titers were measured using serum samples treated with dithiothreitol, while IgM titers were determined from untreated samples. Antibody titers were evaluated every day after initiation of the conditioning protocol.

4. Estimated glomerular filtration rate and proteinuria
Graft function was evaluated by considering the estimated glomerular filtration rate (eGFR) and level of proteinuria. Serum creatinine levels were measured by the Jaffe method on a Hitachi 7600-210 autoanalyzer (Hitachi Co. Ltd., Tokyo, Japan) using Daiichi creatinine (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan). eGFR was estimated from the serum creatinine levels using the Cockroft-Gault equation.
the abbreviated Modification of Diet in Renal Disease formula [7]. Renal function after the operation was categorized into the immediate recovery of graft function (IGF) or slow recovery of graft function (SGF) group on the basis of the eGFR on post-transplant day (POD) 14. Delayed recovery of graft function (DGF) was defined as the need for dialysis within 7 days after transplantation. The level of proteinuria was measured by the semiquantitative method using an automated urine analyzer. The reflectance of the surface of URiSCAN Super test strips (YD Diagnostics, Yon- gin, Korea) was evaluated using a reflectance photometer after the strip was reacted with the patients' urine samples.

RESULTS

1. Characteristics of recipients and donors
Information on the recipients is provided in Table 1. Of the 12 recipients, 7 were women and 5 were men. The median age of the recipients was 51 yr (average age, 48.75 yr; range, 23-60 yr). All patients received major ABO-mismatched grafts, with no weak ABO subgroups among the donors. No patient showed hyperacute rejection after transplantation, and loss of grafts did not occur during the hospitalization period.

2. Anti-A/B antibody titers
Anti-A/B antibody titers were recorded on the day before initiation of PE and IVIG administration, the day of transplantation, the time of discharge from hospital, and at 1 month after transplantation (Table 1). The initial anti-A/B antibody titers of the patients were 1:8-1:128, and the titers decreased in response to PE and IVIG administration to 1:8 in all patients. The average number of pre-transplantation PE and IVIG treatments was 4.0 ±0.89 (range 3-5). In general, the higher the initial antibody titer, the greater the number of pre-transplantation treatments required. However, patient 2 needed 5 treatments of PE and IVIG before transplantation due to a low response to treatment. Most of the patients’ antibody titers at the time of discharge

| Patient number | Donor ABO | Recipient ABO | Recipients | Initial titers* | Number of pre-op PE and IVIG† | Titer at transplantation* | Number of post-op PE and IVIG‡ | Titer at discharge from hospital* | Titer at 1 month after transplantation* |
|---------------|-----------|--------------|------------|----------------|------------------------------|--------------------------|--------------------------------|----------------------------------|---------------------------------------|
| 1             | B+        | A+           | F, 58      | 1:64 1:64      | 5                            | 1.2 1.2                    | 0                             | 1.2 1.2                          | 1.2 1.2                               |
| 2             | AB+       | A+           | M, 60      | 1:8 1:16       | 5                            | 1.2 1.2                    | 1 (POD#9)                    | 1.2 1.8                          | 1.2 8                                 |
| 3             | A+        | B+           | F, 47      | 1:32 1:16      | 4                            | 1.2 1.4                    | 0                             | 1.2 1.8                          | 1.2 1.4                               |
| 4             | AB+       | B+           | M, 51      | 1:128 1:64     | 4                            | 1.2 1.4                    | 2 (POD#5, 8)                 | 1.4 1.16                         | 1.4 1.16                              |
| 5             | A+        | B+           | M, 47      | 1:16 1:4       | 3                            | 1.2 1.2                    | 2 (POD#5, 15)                | 1.8 1.4                          | 1.16 1.8                              |
| 6             | A+        | O+           | F, 60      | 1:128# 1:128#  | 5                            | 1.4# 1.8#                  | 1 (POD#6)                   | 1.16# 1.16#                      | 1.16# 1.16#                          |
| 7             | A+        | B+           | M, 56      | 1:16 1:4       | 4                            | 1.4 1.4                    | 0                             | 1.2 1.2                          | 1.4 1.2                               |
| 8             | A+        | O+           | F, 46      | 1:64# 1:64#    | 5                            | 1.2# 1.4#                  | 1 (POD#6)                   | 1.4# 1.32#                       | 1.4# 1.32#                           |
| 9             | B+        | A+           | M, 51      | 1:32 1:2       | 3                            | 1.2 1.2                    | 0                             | 1.1 1.2                          | 1.1 1.2                               |
| 10            | B+        | A+           | M, 52      | 1:16 1:4       | 3                            | 1.1 1.1                    | 0                             | 1.1 1.4                          | 1.1 1.2                               |
| 11            | B+        | O+           | M, 54      | 1:32# 1:128#   | 5                            | 1.1# 1.2#                  | 0                             | 1.2# 1.8#                       | 1.2# 1.8#                            |
| 12            | B+        | A+           | F, 40      | 1:8 1:2        | 3                            | 1.1 1.4                    | 0                             | 1.1 1.4                          | 1.1 1.2                               |

*Antibody titers assessed using the tube method; †Number of pre-transplant PE and IVIG treatments; ‡Number of post-transplant PE and IVIG treatments; #The anti-A antibody titers; †The anti-B antibody titers.

Abbreviations: pre-op, pre-operative; post-op, post-operative; PE, plasma exchange; IVIG, intravenous immunoglobulin; POD, post-transplant day.
from hospital were higher than the titers at transplantation but lower than their initial titers. Post-transplantation PE and IVIG treatment was performed with 5% albumin solution in order to reduce anti-A/B antibody titers to below 1:16 to avoid rejection in 5 patients (patients 2, 4, 5, 6, and 8). In patients 2 and 5, post-transplantation PE and IVIG administration was effective at lowering antibody titers; however, in patients 4 and 8, anti-A/B antibody titers did not respond to PE and IVIG administration. In patient 6, ABO IgG antibody titers were 1:8 after post-transplantation PE and IVIG administration, but were 1:16 at discharge (Table 2).

3. eGFR and proteinuria
After transplantation, serum creatinine levels, eGFR, and proteinuria showed improvement in all patients. The average creatinine levels at 1 week, 2 weeks, and 1 month after transplantation were 1.30, 1.06, and 1.18 mg/dL, respectively. No patient underwent dialysis after transplantation i.e. no patient showed DGF. The eGFR at POD 14 was computed as over 60 in 10 of the 12 patients, suggesting IGF, while 2 patients (patients 6 and 10) showed eGFR of less than 60, which indicated SGF. Proteinuria due to glomerular damage was negligible in all recipients (Table 3).

**DISCUSSION**

All patients showed graft success and good decrease in serum creatinine level. The average creatinine level at discharge was 1.13 mg/dL, and the average period from transplant to discharge was 18.25 days. The average creatinine level of patients who underwent ABO-compatible kidney transplantation at YUHS between 1997 and 2002 was 1.86 mg/dL and 1.58 mg/dL at 1 week and 1 month after transplant, respectively [8]. The short-term outcomes of ABO-incompatible kidney transplantation were similar to those of ABO-compatible kidney transplantation.

Since the concept of depleting anti-A/B antibody using PE was introduced to overcome the donor-recipient ABO-incompatibility in kidney transplantation, many trials were conducted for several decades. The outcome of ABO-incompatible kidney transplants has been improved and introduction of tacrolimus/mycophenolate mofetil has been regarded as major factor that made a difference [9]. In Korea, successful outcomes without graft loss were reported in ABO-incompatible kidney transplants pretreated with PE, tacrolimus, mycophenolate mofetil and rituximab [10, 11]. Compared to IGF, DGF and SGF i.e. poor early graft function is associated with higher rates of acute rejection and impaired renal allograft survival [12]. We predict good prognosis for patients who showed IGF in this study and poor prognosis for patients with SGF, who may require a renal biopsy for diagnosis of rejection.

Antibody-mediated rejection is a significant risk to the survival of patient and graft. Donor-specific anti-HLA antibodies are more closely associated with rejection than anti-A/B antibodies; nevertheless, prevention of immune reactions due to anti-A/B anti-

---

**Table 3. Serum creatinine levels, eGFR, and urine protein levels of the patients at the time of transplant and at discharge from the hospital**

| Patient number | Creatinine (mg/dL) | eGFR | Urinary protein (semiquantitative) |
|----------------|-------------------|------|-----------------------------------|
|                | At op*            | At discharge†| At POD 14‡ | At op* | At discharge† | At POD 14‡ | At op* | At discharge† | At POD 14‡ |
| 1              | 3.26              | 0.81             | 0.72         | 15.50      | 77.31             | 88.57      | +/-    | -                  |
| 2              | 6.49              | 1.35             | 1.19         | 9.37       | 57.39             | 66.38      | 2+     | -                  |
| 3              | 7.41              | 1.10             | 1.02         | 6.27       | 56.68             | 61.84      | 3+     | -                  |
| 4              | 6.45              | 1.32             | 1.23         | 9.92       | 60.87             | 66.04      | 1+     | -                  |
| 5              | 1.41              | 1.30             | 1.34         | 57.36      | 62.99             | 60.83      | -      | -                  |
| 6              | 10.43             | 1.38             | 1.54         | 4.89       | 50.44             | 44.44      | +/-    | -                  |
| 7              | 4.96              | 0.76             | 0.64         | 9.62       | 83.81             | 102.19     | 2+     | -                  |
| 8              | 4.26              | 1.01             | 1.02         | 11.93      | 59.00             | 62.11      | -      | -                  |
| 9              | 5.13              | 1.05             | 0.93         | 12.71      | 74.00             | 86.00      | 2+     | -                  |
| 10             | 4.92              | 1.29             | 1.45         | 13.28      | 58.00             | 51.00      | 2+     | -                  |
| 11             | 5.53              | 1.27             | 0.73         | 8.00       | 44.00             | 83.00      | -      | +/-               |
| 12             | 5.57              | 0.90             | 0.87         | 8.00       | 69.00             | 72.00      | -      | -                  |

*Measured value at operation; †Measured value at discharge from a hospital; ‡Measured value at POD 14.
Abbreviations: eGFR, estimated glomerular filtration rate; op, operation; POD, post-transplant day.
bodies is crucial for transplant success. ABO antigens are expressed not only on red blood cells but also in various cells such as the endothelial cells of graft organs. ABO-incompatible graft implantation often results in immediate hyperacute rejection, involving failure of graft reperfusion due to thrombosis of the microvasculature [13]. Titters of the anti-A/B IgG antibodies are considered to be more important than titters of IgM. Gloor et al. reported that initial anti-A/B IgG titer of more than 1:256 is significantly associated with the incidence of antibody-mediated rejection [14]. Further, Toki et al. reported that an anti-A/B IgG titer above 1:32 at the time of transplantation is an independent risk factor for antibody-mediated rejection [15]. In this study, patient 6 and patient 11 had the highest initial anti-A/B IgG titters (1:128) and had the lowest eGFR at 50.44 and 44.00, respectively.

PE is used to reduce titters of anti-A/B antibodies, but PE does not eliminate only the anti-A/B antibodies in the plasma. Along with antibodies, plasma constituents are also removed by PE. Theoretically, one-volume PE should lead to removal of 70% of the substances in plasma [16], but actually, efficiency of PE is lowered due to the movement of extravascular substances to the intravascular compartments and resynthesis of plasma substances [17].

Accordingly, 5% albumin solution and AB blood group FFP were used as replacement fluids during PE. Use of albumin involves a minimal risk of infectious disease and rarely causes any allergic reaction. For removing plasma substances without causing any deficits in the plasma, albumin is the most appropriate replacement fluid. Usually, albumin is preferred to FFP because compared to albumin, FFP is associated with higher risk of hypersensitivity reactions and transmission of viral infections [18]. However, in this study, the last 2 PEs immediately before the transplantation were performed with FFP to supply coagulation factors to the patients in order to assuage the worry of surgeons concerning bleeding during operation. Furthermore, soluble ABO antigens present in the FFP can neutralize recipients’ isoagglutinins. Therefore, FFP, as a replacement fluid, can possibly help to reduce the recipient’s anti-A/B antibody titters [17].

IVIG administration can play a role in the reduction of antibody titters, but the exact mechanism is not well defined. It is thought that IVIG suppresses the rebound of antibody titters right after PE. In addition, IVIG is administered after PE to prevent excessive hypogammaglobulinemia.

Post-transplantation PE and IVIG treatments were related to successful renal transplantation during the study period; this may be attributed to a decrease in anti-A/B antibody titters. Lowering the anti-A/B antibody titters by PE and IVIG administration prevented aggravation of antibody-mediated rejection, allowing for successful renal graft functioning. In this study, 5 out of the 12 patients underwent post-transplantation PE and IVIG treatment. Table 2 shows the changes in anti-A/B antibody titters before and after post-transplantation PE and IVIG treatments. Among these 5 patients, 3 patients (patients 2, 5, and 6) showed a decrease in antibody titters after post-transplantation PE and IVIG treatment, but the antibody titters of patient 6 increased right before discharge from hospital. As a result, only 2 patients showed IgG titers within the target range at the time of discharge. Patients 4, 6, and 8 had high ABO IgG titers and required a more number of pre-transplantation PE and IVIG treatments than the other 2 patients. The degree of response to pre-transplantation PE and IVIG treatment appeared to be associated with the degree of response to post-transplantation PE and IVIG treatment.

PE is currently considered as a supportive therapy for ABO-incompatible kidney transplantation. Procedures that remove a recipient’s anti-A/B antibodies are essential for ABO-incompatible kidney transplantation. Protocols for pre-transplantation desensitization should include antibody removal process. PE may help overcome the barrier of ABO incompatibility by removing the recipient’s natural antibodies against the donor’s A and/or B blood group antigens. We suggest that PE be considered as a primary therapy for ABO-incompatible kidney transplantation.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgement

We wish to thank Koung Ae Lee, M.T. for her assistance in PE procedures.

REFERENCES

1. KONOS 2009 annual report. In: Korean Network for Organ Sharing, 2010.
2. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010;25:83-177.
3. Starzl TE, Marchioro TL, Talmage DW, Waddell WR. Splenectomy and thymectomy in human renal homotransplantation. Proc Soc Exp Biol Med 1963;113:929-32.
4. Ishida H, Koyama I, Sawada T, Utsunami K, Murakami T, Sannomiya A, et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000;70:681-5.

5. Huh KH, Kim MS, Kim YS, Kim HJ, Kim HO, et al. Options for successful renal transplantation in recipients with incompatible living donors: Severance Hospital experience. Clin Transpl 2010;323-6.

6. Roback JD, ed. Technical manual. 17th ed. Bethesda: American Association of Blood Banks, 2011:907-911.

7. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-72.

8. Kim SJ, Rha KH, Lee JH, Kim HJ, Kwon K, Kim YS, et al. Favorable outcomes among recipients of living-donor nephrectomy using video-assisted minilaparotomy. Transplantation 2004;77:1725-8.

9. Hur M, Moon HW, Kwon SW. ABO-incompatible kidney transplantation. In: Ortiz J, Andre J, eds. Understanding the complexities of kidney transplantation. InTech, 2011:332-48.

10. Kong JM, Lee DR, Jeong JH, Choi JH, Lee JO, Lee WR, et al. ABO blood group incompatible living donor kidney transplantation without splenectomy. J Korean Soc Transplant 2009;23:71-6.

11. Moon HW, Yun YM, Hur M, Park JH, Lee HW, Chang SH, et al. An experience of ABO-incompatible kidney transplantation using plasma- pheresis and anti-CD20 monoclonal antibody. Korean J Lab Med 2009; 29:585-8.

12. Hellegering J, Visser J, Kloke HJ, D’Ancona FC, Hoitsma AJ, van der Vliet JA, et al. Poor early graft function impairs long-term outcome in living donor kidney transplantation. World J Urol 2012 [Epub ahead of print].

13. Fidler ME, Gloor JM, Lager DJ, Larson TS, Griffin MD, Testor SC, et al. Histologic findings of antibody-mediated rejection in ABO blood-group incompatible living-donor kidney transplantation. Am J Transplant 2004; 4:101-7.

14. Gloor JM, Lager DJ, Fidler ME, Grande JP, Moore SB, Winters JL, et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005;80:1572-7.

15. Toki D, Ishida H, Setoguchi K, Shimizu T, Omoto K, Shirakawa H, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009; 9:567-77.

16. Derksen R, Schuurman H, Meyling F, Struyvenberg A, Kater L. The efficacy of plasma exchange in the removal of plasma components. J Lab Clin Med 1984;104:346-54.

17. Winters JL, Gloor JM, Pineda AA, Stegall MD, Moore SB. Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apher 2004;19:79-85.

18. Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996;7:367-86.